

## Supplementary Materials

**Table S1.** Individual plasma free fatty acids concentration in mice fed control and high-fat diet.

	C14:0	C16:0	C16:1	C18:0	C18:1	C18:2	C20:0	C20:2	C20:4	C22:0	C22:6	C24:0	C24:1
<b>Control</b>	7.08±1.46	70.66±8.03	5.99±1.39	30.02±2.39	69.23±7.29	61.29±11.03	1.09±0.20	2.32±0.37	9.57±1.44	3.90±0.31	1.67±0.20	4.04±1.04	0.16±0.02
<b>HFD</b>	16.81±1.09 <sup>a</sup>	95.14±10.59 <sup>a</sup>	5.27±0.39	60.99±3.99 <sup>a</sup>	141.35±8.55 <sup>a</sup>	137.72±6.58 <sup>a</sup>	3.97±0.30 <sup>a</sup>	2.52±0.27	19.58±1.00 <sup>a</sup>	11.19±0.69 <sup>a</sup>	2.19±0.17 <sup>a</sup>	8.14±0.64 <sup>a</sup>	0.36±0.06 <sup>a</sup>

Values are mean µmol/l of plasma ± SD; n = 8 per group; a - p < 0.05 vs Control

**Table S2.** Impact of GPAT gene silencing on the content of individual acyl-CoA's in mouse gastrocnemius muscle.

	C2:0	C3:0	C4:0	C14:0	C16:0	C16:1	
Control	1.15±0.17	16.59±2.26	0.016±0.004	0.12±0.01	0.85±0.10	0.64±0.06	
HFD(+GPAT)	1.69±0.25 <sup>a</sup>	33.14±5.34 <sup>a</sup>	0.028±0.003 <sup>a</sup>	0.20±0.02 <sup>a</sup>	0.99±0.13 <sup>a</sup>	0.68±0.07	
HFD(-GPAT)	2.18±0.19 <sup>a,b</sup>	22.20±2.68 <sup>a,b</sup>	0.040±0.006 <sup>a,b</sup>	0.26±0.03 <sup>a,b</sup>	1.15±0.10 <sup>a,b</sup>	0.79±0.04 <sup>a,b</sup>	
	C18:0	C18:1	C18:2	C20:0	C22:0	C24:0	C24:1
0.73±0.09	2.59±0.33	1.54±0.18	0.017±0.003	0.022±0.004	0.028±0.004	0.013±0.002	
1.20±0.15 <sup>a</sup>	2.80±0.34	1.96±0.27 <sup>a</sup>	0.019±0.004	0.033±0.005 <sup>a</sup>	0.031±0.005	0.009±0.001	
1.73±0.09 <sup>a,b</sup>	3.37±0.38 <sup>a,b</sup>	2.91±0.34 <sup>a,b</sup>	0.028±0.004 <sup>a,b</sup>	0.039±0.008 <sup>a,b</sup>	0.039±0.007 <sup>a,b</sup>	0.012±0.001 <sup>b</sup>	

Values are mean pmol/mg of tissue ± SD; n = 8 per group; a – p < 0.05 vs Control; b – p < 0.05 vs HFD(+GPAT).

**Table S3.** Impact of GPAT gene silencing on the level of individual short-chain acyl-carnitines in mouse gastrocnemius muscle.

	C2	C3	C4	C5	C5DC	C6	C8	C10	C12
Control	48.14±5.39	3.16±0.34	3.82±0.48	2.41±0.33	0.015±0.0024	0.79±0.09	0.24±0.05	0.17±0.03	0.26±0.02
HFD(+GPAT)	55.04±6.19 <sup>a</sup>	3.80±0.40 <sup>a</sup>	4.42±0.46 <sup>a</sup>	2.80±0.37 <sup>a</sup>	0.018±0.0020 <sup>a</sup>	0.95±0.16 <sup>a</sup>	0.28±0.03 <sup>a</sup>	0.21±0.04 <sup>a</sup>	0.31±0.03 <sup>a</sup>
HFD(-GPAT)	45.44±5.21 <sup>b</sup>	3.42±0.24 <sup>b</sup>	3.63±0.27 <sup>b</sup>	2.31±0.40 <sup>b</sup>	0.016±0.0022	0.81±0.11 <sup>b</sup>	0.21±0.03 <sup>b</sup>	0.17±0.04	0.23±0.03 <sup>a,b</sup>

Values are mean pmol/mg of tissue ± SD; n = 8 per group; a – p < 0.05 vs Control; b – p < 0.05 vs HFD(+GPAT).

**Table S4.** Impact of GPAT gene silencing on the level of individual long-chain acyl-carnitines in mouse gastrocnemius muscle.

	<b>C14</b>	<b>C16</b>	<b>C18</b>	<b>C18:1</b>
<b>Control</b>	1.47±0.20	2.46±0.24	0.72±0.10	6.94±0.59
<b>HFD<sub>(+GPAT)</sub></b>	1.19±0.18 <sup>a</sup>	2.93±0.33 <sup>a</sup>	1.23±0.14 <sup>a</sup>	7.31±0.51
<b>HFD<sub>(-GPAT)</sub></b>	1.28±0.20	3.33±0.37 <sup>a,b</sup>	1.36±0.07 <sup>a,b</sup>	8.40±0.47 <sup>a,b</sup>

Values are mean pmol/mg of tissue ± SD; n = 8 per group; a – p < 0.05 vs Control; b – p < 0.05 vs HFD<sub>(+GPAT)</sub>.

**Table S5.** The impact of GPAT silencing on the content of ceramide molecular species in mouse gastrocnemious muscle.

	d18:1/C14:0	d18:1/C16:0	d18:1/C18:0	d18:1/C18:1	d18:1/C20:0	d18:1/C22:0	d18:1/C24:0	d18:1/C24:1
<b>Control</b>	0.029±0.003	1.94±0.24	16.93±1.53	0.56±0.09	0.27±0.04	0.77±0.13	1.24±0.16	3.83±0.44
<b>HFD(+GPAT)</b>	0.034±0.008	3.20±0.35 <sup>a</sup>	30.27±3.42 <sup>a</sup>	0.67±0.05 <sup>a</sup>	0.57±0.10 <sup>a</sup>	1.45±0.21 <sup>a</sup>	2.55±0.32 <sup>a</sup>	5.08±0.59 <sup>a</sup>
<b>HFD(-GPAT)</b>	0.041±0.004 <sup>a,b</sup>	3.43±0.30 <sup>a</sup>	32.62±4.15 <sup>a</sup>	0.71±0.06 <sup>a</sup>	0.66±0.13 <sup>a</sup>	1.55±0.25 <sup>a</sup>	2.68±0.19 <sup>a</sup>	5.19±0.58 <sup>a</sup>

Values are mean pmol/mg of tissue +/- SD; n=8 per group; a – p<0.05 vs Control; b – p<0.05 vs HFD(+GPAT).